Key Points
- Twist Bioscience director Jan Johannessen sold 12,000 shares on May 12 at an average price of $56.12, totaling about $673,440. After the sale, he still held 17,754 shares, a 40.33% reduction in his stake.
- The company recently reported quarterly earnings of ($0.71) per share, missing analyst expectations, though revenue of $110.72 million beat estimates and rose 19.3% year over year.
- Despite the insider sale, analysts remain broadly positive: seven Buy ratings and one Sell rating give Twist Bioscience a consensus “Moderate Buy” with a target price of $56.57.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) Director Jan Johannessen sold 12,000 shares of the business's stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total transaction of $673,440.00. Following the completion of the sale, the director directly owned 17,754 shares of the company's stock, valued at $996,354.48. This represents a 40.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Twist Bioscience Stock Performance
Twist Bioscience stock opened at $52.95 on Friday. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $3.30 billion, a PE ratio of -39.81 and a beta of 2.22. The firm has a fifty day simple moving average of $51.83 and a two-hundred day simple moving average of $42.45. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $66.06.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The firm had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business's revenue was up 19.3% on a year-over-year basis. During the same period last year, the company posted ($0.66) earnings per share. Research analysts expect that Twist Bioscience Corporation will post -1.86 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. Quarry LP bought a new position in Twist Bioscience during the third quarter valued at approximately $28,000. Smartleaf Asset Management LLC raised its position in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock worth $29,000 after acquiring an additional 442 shares during the period. Strs Ohio bought a new position in Twist Bioscience in the first quarter worth approximately $33,000. Strategic Advocates LLC raised its position in Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company's stock worth $34,000 after acquiring an additional 906 shares during the period. Finally, SBI Securities Co. Ltd. raised its position in Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company's stock worth $44,000 after acquiring an additional 571 shares during the period.
Analyst Ratings Changes
A number of equities research analysts have weighed in on TWST shares. Weiss Ratings restated a "sell (d-)" rating on shares of Twist Bioscience in a report on Friday, March 27th. Leerink Partners upgraded shares of Twist Bioscience from a "market perform" rating to an "outperform" rating and set a $70.00 price objective on the stock in a report on Tuesday, May 5th. Barclays upped their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock an "overweight" rating in a report on Monday, May 4th. Evercore upped their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an "outperform" rating in a report on Tuesday, February 3rd. Finally, Robert W. Baird increased their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an "outperform" rating in a report on Tuesday, May 5th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus target price of $56.57.
Get Our Latest Research Report on Twist Bioscience
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
